| Literature DB >> 32028579 |
Marta Nardini1,2, Sara Perteghella3, Luca Mastracci4,5, Federica Grillo4,5, Giorgio Marrubini3, Elia Bari3, Matteo Formica4,6, Chiara Gentili7,8, Ranieri Cancedda9, Maria Luisa Torre3, Maddalena Mastrogiacomo1,2,8.
Abstract
Standard treatments of chronic skin ulcers based on the direct apEntities:
Keywords: advanced wound dressing; alginate; human platelet lysate; regenerative medicine; sericin; wound healing
Year: 2020 PMID: 32028579 PMCID: PMC7076531 DOI: 10.3390/pharmaceutics12020120
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Composition of the biomembranes. Biomembranes percentage composition (w/v) of solution employed for biomembrane preparation and percentage composition (w/w %) of freeze-dried biomembranes.
| Type of Biomembrane | Name | Solution Percentage Composition ( | Membrane Percentage Composition ( | ||||
|---|---|---|---|---|---|---|---|
| Alg | SS | PL | Alg | SS | PL | ||
| Control | Alg/SS | 1 | 1 | 0 | 50 | 50 | 0 |
| Treated | Alg/SS/PL | 1 | 1 | 2 | 25 | 25 | 50 |
| Treated | Alg/PL | 1 | 0 | 1 | 50 | 0 | 50 |
Figure 1Fourier transform infrared (FTIR) spectroscopy. The analysis was performed on single components (SS, PL and Alg) (a) and biomembranes (b) The IR spectra where obtained in the spectral region of 4000–650 cm−1.
Figure 2Protein release analysis. Release of total proteins from Alg/PL and Alg/SS/PL biomembranes at different time incubation in physiological solution at 37 °C and 5% CO2. The total protein content was determined with Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA) in the incubation media collected at different times. The experiments were performed in triplicate on three different batches of biomembranes.
Figure 3Growth factors release analysis. Release of growth factors from Alg/PL and Alg/SS/PL biomembranes after incubation in physiological solution at 37 °C and 5% CO2. The amounts of Vascular Endothelial Growth Factor (VEGF) (a), Platelet-derived Growth Factor-BB (PDGF-BB) (b) and Transforming Growth Factor Beta 1 (TGF-β1) (c) released in the incubation medium at different time points were determined by ELISA assay. The curves represent the release during time of the three different factors expressed as percentage of the maximum release: VEGF (d), PDGF-BB (e), TGF-β1 (f), **** p < 0.0001, *** p < 0.001, * p < 0.05.
Figure 4Cell viability with biomembrane components. Analysis of bone marrow mesenchymal stromal cells (BMSC) (a) and human skin fibroblasts (hFB) (b) viability and capacity of cells to proliferate following the PL stimulation in the presence of SS. Cells were maintained up to 72 h in Serum-free medium (SFM), or SFM supplemented with PL (PL), Sericin (SS), PL and Sericin (PL:SS). Cell viability was determined by a Thiazolyl blue staining (MTT assay), **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05.
Figure 5Evaluation of cell proliferation. Proliferation rate of synchronized growth arrested BMSC after stimulation with Sericin (SS), Platelet Lysate (PL), and PL:SS. Data are presented as percentage of the highest growth observed at 48 h in cells stimulated with PL alone. We determined growth rates of three different synchronized primary BMSC cultures in triplicate, **** p < 0.0001, ** p < 0.01.
Figure 6WB analysis of Cyclin D1. Level of Cyclin D1 expression 8 and 24 h after stimulation of synchronized BMSC with SS, PL and with PL:SS. Results are expressed as percentage of the highest expression observed 8 h after stimulation with PL. Levels of Cyclin D1 expression were determined by Western Blot. We performed WB analysis on three different primary cell cultures, *** p < 0.001, ** p < 0.01.
Figure 7Protection against oxidative stress. Viability of BMSC (panel a) and hFB (panel b) after an oxidative stress induced by H2O2 (1 mM) and the effect of a contemporary treatment with Sericin (SS), Platelet Lysate (PL), and PL:SS. Cell viability was determined by MTT assay, **** p < 0.0001, *** p < 0.001, ** p < 0.01.
Figure 8Histological analysis of skin lesions. Histology of lesions treated with Alg/SS and Alg/SS/PL biomembranes. Bioptic sample sections were cut at 3 μm thickness and stained with haematoxylin-eosin. Images were acquired at 5× magnification (0.5 mm scale bar) and 20× magnification (0.1 mm scale bar).
Figure 9Quantification of histological parameters. Histology of the lesions treated with Alg/SS and Alg/SS/PL biomembranes; evaluation and statistical analyses of specific parameters suggested by Abramov et al. [24]: inflammation, defined in an early phase (a) and a late one (b); granulation tissue, intended as amount (c) and maturation of granulation tissue (d); collagen deposition (e); re-epithelialization (f) and neo-vascularization (g). All evaluations were reported in the plot as difference between the PL treated and the control lesions, *** p < 0.001, ** p < 0.01, * p < 0.05.